Stock Analysis
BioMarin Pharmaceuticals IncBMRN
P/E 145.05×· 5Y range 15.74–1,064.81×· 55th percentile of history
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy35 analystsP/E 145.1× sits at the 55th percentile of its 5.065023956194388-year history.
Cash covers 21% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, fairly valued
Strengths
- Financial Health72
- Quality60
Risks
- Profitability21
- Growth45
Mixed picture — no clear quality or value edge.
Market context
-2.4% today· Z 0.9σ
Bull Case
- ✓Revenue CAGR 14.9% — durable top-line growth
- ✓Interest coverage 24.9× — debt well covered
What's happening with BMRN
Profile
profitability, moat and growth lag behind.
How is each axis scored?
- Valuation52/100 · Moderate
- P/E vs own history (55th pct)12/25
- FCF yield (6.9%)20/25
- P/S (3.1x)20/25
- EV/EBIT (93.7x)0/25
- Growth45/100 · Weak
- Revenue CAGR (14.9%)20/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (833.0%)25/25
- Profitability21/100 · Weak
- ROIC (1.2%)5/25
- ROE (1.2%)5/25
- Net margin (2.1%)6/25
- Operating margin (4.4%)5/25
- Financial Health72/100 · Moderate
- Altman Z (1.68)10/25
- Current ratio (2.39)25/25
- Interest coverage (24.9x)25/25
- Net cash / debt (D/A 28%)12/25
- Quality60/100 · Moderate
- Piotroski F (4/9)10/25
- Beneish M (-2.61)25/25
- FCF conversion (1012%)25/25
- Margin stability (σ 97.0%)0/25
- Moat30/100 · Weak
- ROIC >12% years (0/10 yrs)0/25
- Median gross margin (78.8%)25/25
- FCF-positive years (5/10 yrs)5/25
- Worst-year net margin (worst -56.4%)0/25
Risk Flags
- ⚠Altman Z 1.7 — distress-zone balance sheet
- ⚠SBC 6.3% of revenue — real dilution cost
- ⚠5 loss-making years in recent history
About BioMarin Pharmaceuticals Inc
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. Show more
BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Headquarters: NOVATO, CA · Employees: 3,221 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
52CP/E (TTM)145.9xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 15.7x–1064.8x · 55th pct
P/FCF15.2xB
Grade B: FairPrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.9%A
Grade A: ValueTTM (OCF − CapEx) / Market Cap — vs own 5Y history: 0.1%–8.2% · 88th pct
P/S (TTM)3.13xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 3.0x–11.0x · lowest in history
EV/EBIT93.7xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 28.6x–95.0x · 97th pct
EV/Sales4.2xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.6xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.68xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio4.10D
Grade D: ExpensiveFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
21EROIC1.2%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE1.2%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA0.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin2.1%D
Grade D: LowNet Income / Revenue
Operating Margin4.4%D
Grade D: LowTTM EBIT / TTM Revenue
Gross Margin76.1%A
Grade A: PremiumGross Profit / Revenue
FCF Margin21.7%A
Grade A: HighFCF / Revenue
True FCF Margin15.3%A
Grade A: HighTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
45D+Revenue CAGR14.9%C
Grade C: OkCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth833.0%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+4.6%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income295.1%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue6.3%C
Grade C: MedTTM stock-based comp / TTM Revenue
Financial Health
72B+Altman Z-Score1.68D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio2.39xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio1.16xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage24.9xA
Grade A: StrongEBIT/Interest. >10 Strong
Debt Repayment4.5yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT22.3xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity0.66xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.21xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
60BPiotroski F-Score4/9C
Grade C: AverageFinancial strength 0–9. >7 Strong
Beneish M-Score-2.61A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion1011.6%A
Grade A: StrongFCF / Net Income
Margin Stability97.0%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue3.5%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.38xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Friberg Gregory R Filed | Friberg Gregory R | Tax withholding | -4086 | |
Plenge Robert M Filed | Plenge Robert M | Grant / award | +6.1K | |
Davis George Eric Filed | Davis George Eric | SellOpen market sale | -17557 | |
Countouriotis Athena Filed | Countouriotis Athena | Grant / award | +7.5K | |
Walbert Timothy P Filed | Walbert Timothy P | Grant / award | +7.5K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Ho Maykin Filed | Ho Maykin | Grant / award | +7.5K | |
HOMBACH ROBERT J. Filed | HOMBACH ROBERT J. | Grant / award | +7.5K | |
Enyedy Mark J Filed | Enyedy Mark J | Grant / award | +7.5K |
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
30DROIC >12% Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)78.8%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years5/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-56.4%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$0.38
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$4.52
Cash & short-term investments per share (Finnhub)
Book Value / Share$32.66
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$4.20B
Total debt obligations (short + long term)
Cash & Equiv.$874.00M
Cash and short-term investments
Net Debt$3.33B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$6.32B
Shareholders' equity (book value)
Asset / Liability2.17xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$10.65B
Current Market Capitalization
Beta0.23B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: BioMarin Pharmaceuticals Inc (BMRN)
BMRN is down 2.44% at the last close. Piotroski F-Score of 4/9 indicates mixed fundamentals for BioMarin Pharmaceuticals Inc. Altman Z-Score of 1.68 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of -2.61 suggests a low likelihood of earnings manipulation.
- BioMarin Pharmaceuticals Inc converts about 22% of revenue into free cash flow — strong cash generation.
- Takes ~4.5 years to repay net debt from free cash flow.
- BioMarin Pharmaceuticals Inc posted a net loss in 5 of 10 available completed fiscal years (2016–2025).
See how BMRN ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all BMRN moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 15 | Regular | 56.31 | +2.11% | 2.43 |
| Oct 15 | After-hours | 56.11 | +1.76% | 2.15 |
| Oct 14 | After-hours | 55.25 | +1.60% | 2.18 |
| Oct 12 | After-hours | 55.62 | +1.51% | 2.14 |
Frequently Asked Questions about BMRN
What is the current BioMarin Pharmaceuticals Inc (BMRN) stock price?
BMRN is trading at $54.68 at the last market close, down 2.44% on the session. PreMarketPrice tracks BMRN pre-market, intraday and after-hours prices.
Is BMRN stock a buy right now?
PreMarketPrice's quantitative model rates BioMarin Pharmaceuticals Inc's financial health at 72/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is BMRN stock overvalued?
BioMarin Pharmaceuticals Inc trades at a trailing P/E of 145.9 and our valuation score rates it 52/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does BioMarin Pharmaceuticals Inc report earnings?
No confirmed earnings date is currently scheduled for BMRN. The Earnings section lists recent reports and updates as dates are announced.
What sector does BioMarin Pharmaceuticals Inc operate in?
BioMarin Pharmaceuticals Inc operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does BioMarin Pharmaceuticals Inc do?
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases.
About BioMarin Pharmaceuticals Inc (BMRN) Stock
BioMarin Pharmaceuticals Inc (BMRN) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, BioMarin Pharmaceuticals Inc is trading at $54.68, down 2.44% on the day with a market capitalization of $10.7 billion. The financial health score for BMRN is 72/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for BMRN stock.
BMRN Stock Analysis & Key Metrics
On PreMarketPrice, you can track BioMarin Pharmaceuticals Inc (BMRN) across multiple dimensions:
- Pre-market price & movement: Real-time BMRN stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for BMRN with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for BioMarin Pharmaceuticals Inc across multiple reporting periods.
- Financial health score: A composite score of 72/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for BMRN.
- Sector peers: Compare BMRN against 6 other healthcare stocks on key financial metrics.
Is BMRN a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate BioMarin Pharmaceuticals Inc (BMRN) as an investment. The financial health score of 72/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.BioMarin Pharmaceuticals Inc (BMRN) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.